Clinical Trial Detail

NCT ID NCT02089230
Title MEK Inhibitor 162 Relapsed and/or Refractory Acute Myeloid Leukemia (AML) and Poor Prognosis, Not Suitable for or Unwilling to Receive Standard Therapy
Recruitment Completed
Gender both
Phase Phase Ib/II
Variant Requirements Yes
Sponsors M.D. Anderson Cancer Center
Indications

myelodysplastic/myeloproliferative neoplasm

acute myeloid leukemia

acute lymphoblastic leukemia

Therapies

Binimetinib

Age Groups: senior adult

Additional content available in CKB BOOST